Zobrazeno 1 - 10
of 101
pro vyhledávání: '"E A Copelan"'
Publikováno v:
Blood. 75:1583-1586
Serum immunoglobulin (Ig) G subclass levels were measured in a radial immunodiffusion assay in 25 leukemic patients before and after allogenic bone marrow transplantation. All patients received a conditioning regimen of busulfan and cyclophosphamide
Autor:
E, Berman, R A, Clift, E A, Copelan, P D, Emanuel, H P, Erba, M J, Glenn, P L, Greenberg, R J, Jones, S, O'Brien, H I, Saba, R, Schilder, D S, Snyder, R J, Soiffer, M S, Tallman, M, Wetzler, F, Ravandi-Kashani, H, Kantarjian, M, Talpaz
Publikováno v:
Oncology (Williston Park, N.Y.). 14(11A)
Autor:
C Nichols, C F LeMaistre, A Smith, M Lange, J. E. Anderson, J M Fernandez Ranada, Julie M. Vose, W Longo, L. Garrison, E A Copelan, A Granena, A N Pandite, D L Topolsky, T Ahmed, R. B. Geller, I Tabbara, P. J. Bierman, Patrick J. Stiff, M W Schuster, R A Beveridge, M. E. Lebsack, A. Keating
Publikováno v:
Journal of clinical oncology : official journal of the American Society of Clinical Oncology. 15(4)
PURPOSE A phase III trial to compare PIXY321 with granulocyte-macrophage colony-stimulating factor (GM-CSF) following high-dose therapy and autologous bone marrow transplant (ABMT) was conducted to evaluate the time to hematopoietic recovery. PATIENT
Autor:
E A, Copelan, S L, Penza, P J, Elder, P S, Belt, M D, Scholl, D M, Hehmeyer, S A, Ezzone, T P, Bechtel, B R, Avalos
Publikováno v:
Bone marrow transplantation. 18(5)
Between March 1984 and March 1995, 76 patients with advanced acute myelogenous, acute lymphoblastic, or chronic myelogenous leukemia underwent allogeneic marrow transplantation from HLA-identical or one-antigen mismatched sibling or unrelated donors.
Autor:
J L, Klein, B R, Avalos, P, Belt, C A, Taylor, S A, Ezzone, M D, Scholl, J, Fisher, D, Young, E A, Copelan
Publikováno v:
Bone marrow transplantation. 17(4)
Two major problems of unrelated donor transplantation have been an increased incidence of GVHD and graft failure. Even with HLA identity by microlymphocytotoxicity assay and non-reactive MLC, URD marrow transplant recipients have a higher incidence o
Autor:
E A, Copelan, E A, McGuire
Publikováno v:
Blood. 85(5)
Despite reports to the contrary, only a small minority of adults with ALL are currently cured. Results have improved modestly with more intensive postremission chemotherapy and with tailoring of protocols in individuals with specific subsets of ALL.
Autor:
C A, Keever, N, Leong, I, Cunningham, E A, Copelan, B R, Avalos, J, Klein, N, Kapoor, P W, Adams, C G, Orosz, P J, Tutschka
Publikováno v:
Bone marrow transplantation. 14(1)
We describe the recipient of a marrow graft from an HLA-serologically identical unrelated donor from whom highly potent host-reactive CTL of donor origin were isolated in association with acute GVHD. Extensive sequence and biochemical analysis of the
Autor:
E A, Copelan, T P, Bechtel, J P, Klein, J L, Klein, P, Tutschka, N, Kapoor, N C, Featheringham, B R, Avalos
Publikováno v:
Bone marrow transplantation. 13(1)
Between May 1987 and September 1989, 72 patients undergoing marrow transplantation at a single institution were randomized to receive 50 mg/kg of a commercial gammaglobulin preparation or placebo daily in four divided doses for 28 days following tran
Publikováno v:
Bone marrow transplantation. 12(6)
Ten patients with AML or CML aged 40-55 years underwent allogeneic marrow transplantation from HLA-identical siblings following a preparation regimen of busulfan 16 mg/kg and cyclophosphamide (CY) 90 mg/kg. The CY dose was substantially lower than ha
Autor:
C A, Keever, J, Klein, N, Leong, E A, Copelan, B R, Avalos, N, Kapoor, I, Cunningham, P J, Tutschka
Publikováno v:
Bone marrow transplantation. 12(3)
The mechanism by which GVHD augments the graft-versus-leukemia (GVL) effect of marrow transplants has not been ascertained. One possibility involves the secondary activation of natural killer (NK) cells by cytokines released during the GVHD process.